Axonics SNM System for Overactive Bladder

This trial evaluates the safety and performance of the Axonics SNM System, a device designed to assist individuals with overactive bladder. Researchers aim to determine if the device maintains its effectiveness over time for those with implants. Individuals with overactive bladder who have not found success with other treatments might be suitable candidates. Participants must be prepared to visit clinical centers for follow-up assessments. As an unphased trial, this study provides a unique opportunity to contribute to the understanding of a promising treatment for overactive bladder.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that the Axonics SNM System, used to treat overactive bladder, is safe for people. In an important study, no serious problems related to the device were reported after two years, indicating that the treatment did not cause major issues for participants during that time.

The FDA has already approved the Axonics SNM System for treating urinary problems, suggesting it is generally well-tolerated. While minor side effects can occur, data indicates that the device usually does not cause significant harm.

The Axonics SNM System for overactive bladder is unique because it uses sacral neuromodulation, which involves implanting a small device to regulate nerve activity. Unlike standard treatments like medications or lifestyle changes, which can have variable effectiveness and side effects, this system directly targets the nerves controlling bladder function. Researchers are excited because this approach offers a long-term solution with the potential for fewer side effects, aiming to improve quality of life for individuals with overactive bladder.

Research has shown that the Axonics SNM System effectively manages overactive bladder symptoms. In one study, 89% of participants experienced significant improvements in bladder control. Another study found that 90% of individuals noticed substantial improvements within six months. Long-term data confirms its safety and effectiveness for over two years. Additionally, up to 82% of patients reported at least a 75% improvement in symptoms, with 37% becoming completely dry. These findings strongly support the Axonics SNM System's effectiveness in treating overactive bladder.⁶⁷⁸⁹¹⁰